Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

被引：0
|
作者：
Scott T. Tagawa
Krishnan Ramaswamy
Ahong Huang
Jack Mardekian
Neil M. Schultz
Li Wang
Rickard Sandin
Stanislav Lechpammer
Daniel J. George
机构：
[1] Weill Cornell Medicine,
[2] Pfizer Inc.,undefined
[3] STATinMED Research,undefined
[4] Astellas Pharma Inc.,undefined
[5] Pfizer AB.,undefined
[6] Pfizer Inc.,undefined
[7] Duke Cancer Institute,undefined
[8] Duke University School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1032 / 1040
页数：8
相关论文
共 50 条
  • [21] Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Buonerba, Carlo
    Sonpavde, Guru
    Pond, Gregory Russell
    Pagliuca, Martina
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Daniele, Bruno
    Federico, Piera
    Morelli, Franco
    Carteni, Giacomo
    Ferro, Matteo
    Lucarelli, Giuseppe
    Bellelli, Teresa
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Hospitalization costs among chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI)
    Ramaswamy, Krishnan
    Gilligan, Adrienne M.
    Lenhart, Gregory
    Flanders, Scott
    Schultz, Neil M.
    Mardekian, Jack
    Kent, Shia T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer
    von Hardenberg, Jost
    Schwartz, Maike
    Werner, Thorsten
    Fuxius, Stefan
    Mueller, Markus
    Bolenz, Christian
    Weiss, Christel
    Heinrich, Elmar
    PROSTATE, 2016, 76 (07): : 613 - 619
  • [24] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [25] Enzalutamide: A Review of Its Use in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Keating, Gillian M.
    DRUGS & AGING, 2015, 32 (03) : 243 - 249
  • [26] Hospital admissions (HA) among chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI).
    Quek, Ruben G. W.
    Gilligan, Adrienne M.
    Kent, Shia T.
    Gregory, Christopher
    Schultz, Neil M.
    Flanders, Scott
    Brown, Bruce A.
    Wong, Elaine Karol
    Barlev, Arie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
  • [28] Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy -pretreated metastatic castration-resistant prostate cancer patients
    Stuyckens, Kim
    Saad, Fred
    Xu, Steven
    Ryan, Charles J.
    Smith, Matthew R.
    Griffin, Thomas W.
    Yu, Margaret K.
    Vermeulen, An
    Nandy, Partha
    Poggesi, Italo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [29] Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
    Schultz, Neil M.
    Flanders, Scott C.
    Wilson, Samuel
    Brown, Bruce A.
    Song, Yan
    Yang, Hongbo
    Lechpammer, Stanislav
    Kassabian, Vahan
    ADVANCES IN THERAPY, 2018, 35 (10) : 1639 - 1655
  • [30] Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
    Ueda, Yujiro
    Matsubara, Nobuaki
    Tabata, Ken-Ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    CLINICAL GENITOURINARY CANCER, 2017, 15 (02) : 320 - 325
12345